BofA raised the firm’s price target on Idexx Laboratories (IDXX) to $790 from $700 and keeps a Neutral rating on the shares following what the firm calls a “clean, straightforward beat with nothing to nit-pick” in Q3. Though the firm says it can’t “offer any push-back” with performance this quarter, it believes that valuation has appropriately priced in this strength given that the stock is now trading at greater than 55-times current year EPS estimates.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- Idexx Laboratories price target raised to $785 from $745 at Leerink
- Idexx Laboratories price target raised to $775 from $700 at Stifel
- Early notable gainers among liquid option names on November 3rd
- Idexx Laboratories reports Q3 EPS $3.40, consensus $3.14
- Idexx Laboratories raises FY25 EPS view to $12.81-$13.01 from $12.40-$12.76